
GH Stock Forecast & Price Target
GH Analyst Ratings
Bulls say
Guardant Health is expected to see strong growth in their biopharma business and their Reveal test, but increased competition and potential marketing expenses could hinder their growth. However, the company is taking steps to enhance their offerings and expand into new markets, such as the inclusion of their Shield CRC test in industry guidelines and potential payor mandates. Despite potential challenges, analysts believe GH has a positive outlook and could see their shares trading at a higher price in the future.
Bears say
Guardant Health is a leader in the liquid-based testing market, but their competitors are catching up and could impact their future market share. Additionally, the company's high reliance on government regulations and reimbursements could impact their future growth and profitability. The recent failure of a clinical trial for one of their products and potential challenges related to FDA regulations also pose risks to the company's success.
This aggregate rating is based on analysts' research of Guardant Health Inc and is not a guaranteed prediction by Public.com or investment advice.
GH Analyst Forecast & Price Prediction
Start investing in GH
Order type
Buy in
Order amount
Est. shares
0 shares